By Katherine Hamilton
Atea Pharmaceuticals is reviewing strategic opportunities after cutting a quarter of its workforce.
The Boston biopharmaceutical company, which develops oral antiviral treatments, said Wednesday it has engaged an independent global investment bank to identify possible opportunities, including partnerships on its Phase 3 program for a treatment of patients with HCV.
It also reduced 25% of its employees during the first quarter in an effort to reduce costs. The reduction is expected to save $15 million through 2027, Atea said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 26, 2025 14:18 ET (18:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.